口服1,6-二磷酸果糖对动物肝损伤模型的保护作用

摘要/Abstract

摘要： 目的研究长期口服1, 6-二磷酸果糖(FDP)对不同的肝损伤模型的影响, 探索口服FDP作为慢性肝损伤保护药物的可能性。方法用CCl4所致的肝损伤模型来观察FDP对慢性肝损伤的作用; 用D-半乳糖(GalN)和脂多糖(LPS)所致的小鼠肝损伤模型来评价FDP对急性肝损伤的作用。结果在CCl4所致的大鼠慢性肝损伤模型中, FDP (1 – 4 g·kg^-1·d^-1 ig)连续用药10周, 可明显降低血清中病理性升高的ALT、AST、γ-GT、T-BIL和ALP的含量, 同时升高病理性降低的TP、ALB和T-CHO的水平; 并明显降低肝组织中羟脯氨酸的含量; FDP 4.0 g·kg^-1·d^-1可明显减少肝硬化发生率和减轻肝组织病理改变。在GalN所致的小鼠急性肝损伤模型中, FDP 1.0 – 4.0 g·kg^-1·d^-1 (ig 3 d) 显著降低血清中ALT和AST的水平(P<0.01)和肝系数, 4.0 g·kg^-1·d^-1可明显减轻肝细胞超微结构的病理性改变。在LPS所致的小鼠急性肝损伤模型中, FDP最大剂量(4.0 g·kg^-1·d^-1, ig 12 d)可明显降低血清中的ALT。结论本研究首次证明了长期口服FDP对CCl4所致的慢性肝损伤具有保护作用, 同时证实了它对急性肝损伤的保护作用, 提示口服FDP对不同原因引起的肝损伤有效, 有可能作为口服肝保护药用于临床。

关键词: 肝损伤, 肝损伤, 肝损伤, 口服1,6-二磷酸果糖, 口服1,6-二磷酸果糖, 口服1,6-二磷酸果糖, 动物模型, 动物模型, 动物模型

Abstract:

Aim To investigate the effects of FDP on different liver injury models to explore the possibility of FDP used as an oral liver protective agent. Methods Chronic liver injury model in ratswas induced by carbon tetrachloride (CCl4); Acuteliver injury model in micewas induced by aminogalactose (GaIN) or lipopolysaccharide (LPS). Results In CCl4 -induced chronic liver injury model, FDP (1 – 4 g·kg^-1·d^-1, q.d., for 10 weeks) significantly lowered ALT, AST, γ-glutamyl transpeptidase(γ-GT), alkaline phosphatase (ALP), and total bilirubin (T-BIL)in serum compared with vehicle; simultaneously it evidently elevated abnormal total protein (TP), albumin (ALB) and total cholesterol ( T-CHO ) levels in serum; italso dose-dependently reduced hydroxyproline contentsin hepatic tissue. 4 g·kg^-1·d^-1 of FDP apparently decreased incidence of hepatic cirrhosis,and alleviated pathological changes of liver tissue. In GaIN-induced model, 1.0 – 4.0 g·kg^-1·d^-1 of FDP (bid, for 3 d) significantly lowered alanine aminotransferase ( ALT ) and aspartate aminotransferase ( AST ) levels in serum; it also decreased liver coefficient.4.0 g·kg^-1·d^-1 of FDPsignificantly alleviated pathological changes of cell ultra-structures. In LPS-induced model, only high dose of FDP(4.0 g·kg^-1·d^-1, bid, for 12 d) significantly decreased ALT level in serum. Conclusion This study first demonstrated the protective effectof oral FDP on chronic liver injury caused by CCl4 , and confirmed its effect on acute liver injury at the same time, suggesting thatLong-term oral FDPis efficacious against liver injuryinduced by different factorsand can be used as an oral liver protective agent in clinic.

Key words: liver injury, liver injury, oral fructose-1,6-diphosphate, oral fructose-1,6-diphosphate, animal models, animal models

中图分类号:

R965

R975.5

Supporting: ^*Corresponding author. Tel.: 86-10-82802652

刘晓岩, 李凤云, 池志宏, 王银叶^*. 口服1,6-二磷酸果糖对动物肝损伤模型的保护作用[J]. .

LIUXiao-yan, LI Feng-yun , CHI Zhi-hong, WANG Yin-ye^*. Protective Effects of Oral Fructose-1, 6-diphosphate on Liver Injury in Animal Models[J]. .

参考文献

[1] Izumi Y, Benz AM, Katsuki H, et al. Effects of fructose-1,6-bisphosphate on morphological and functional neuronal integrity in rat hippocampal slices during energy deprivation [J]. Neuroscience, 2003, 116 (2) : 465-475.
[2] Didlake R, Kirchner KA, Lewin J , et al. Attenuation of ischemic renal injury with fructose-1,6-diphosphate [J]. J Surg Res, 1989, 47 (3) : 220-226.
[3] Lazzarino G, Nuutinen ME, Tavazzi B, et al. Preserving effect of fructose-1,6-bisphosphate on high-energy phosphate compounds during anoxia and reperfusion in isolated Langendorff-perfused rat hearts [J]. J Mol Cell Cardiol, 1991, 23 (1) : 13-23.
[4] Sano W, Watanabe F, Tamai H, et al. Beneficial effect of fructose-1,6-bisphosphate on mitochondrial function during ischemia-reperfusion of rat liver [J]. Gastroenterology, 1995, 108 (6) : 1785-1792.
[5] Hardin CD, Roberts TM. Metabolism of exogenously applied fructose-1,6-bisphosphate in hypoxic vascular smooth muscle [J]. Am J Physiol Heart Circul Physiol, 1994, 267 (6 Pt 2) : H2325-2332.
[6] Sola A, BerriosM, Sheldon RA, et al. Fructose-1,6-bisphosphate after hypoxic ischemic injury is p rotective to the neonatal rat brain [J]. Brain Res, 1996, 741 (1-2) : 294-299.
[7] Janz TG, Leasure J, Olson JE. The effects of fructose-1,6-diphosphate on myocardial damage in acute coronary artery occlusion [J]. Resuscitation, 1991, 22 (1) : 45-54.
[8] Markov AK, Brumley MA, Figueroa A, et al. Hemodynamic effects of fructose-1,6-diphosphate in patients with normal and impaired left ventricular function [J]. Am Heart J, 1997, 133 (5) : 541-549.
[9] L iu PH, Zhang H, Chen YZ, et al. The research progression on oral application of fructose-1,6-diphosphate [J]. J Chin Pharm Sci, 2001, 10 (2) : 66-67.
[10] Deng C, Pei L, Liu TX. Evaluation of the effect of fructose-1,6-diphosphate to treat hypoxic ischemic myocardial damage due to neonatal asphyxia [J]. J Pediatr Pharm, 2001, 7 (4) : 17-18.
[11] Bao ZL, Tang GL, Ji CX, et al. Clinical effect observation of fructose-1,6-diphosphate combined with Dan-shen composita on chronic active hepatitis [J]. Shanxi Med J, 2001, 30 (2) : 99-100.
[12] Gong GQ, Zhou S, Su L. The protective effect of oral 1,6-diphosphate fructose on acute liver lesion in mice [J]. Chin J Biochem Pharm , 2001, 22: 178-179.
[13] Fortes CA, Aiub BR, Arrieira A, et al. Alterations in the indexes of apoptosis and necrosis induced by galactosamine in the liver of Wistar rats treated with fructose-1,6-bisphosphate [J]. Hepatol Res, 2003, 25 (1) : 83-91.
[14] De Oliveira JR, Rosa JL, Ambrosio S, et al. Effect of galactosamine on hepatic carbohydrate metabolism: protective role of fructose-1,6-bisphosphate [J]. Hepatology, 1992, 15: 1147-1153.
[15] Roig T, Bartrons R, Bermudez J. Exogenous fructose-1,6-bisphosphate reduces K⁺ permeability in isolated rat hepatocytes [J]. Am J Physiol Cell Physiol, 1997, 273: C473-478.
[16] Obara H, Kato A, Suzuki K, et al. Regulation of albumin gene expression in carbon tetrachloride-induced liver cell injury [J]. Int Hepatol Commun, 1995, 3, 89.
[17] Kesava Raddy G, Enwemeka CS. A simp lified method for the analysis of hydroxyp roline in biological tissues [J]. Clin Biochem, 1996, 29 (3) : 225-229.
[18] Farghali H, Canov N, Kucera T, et al. Nitric oxide synthase inhibitors modulate lipopolysaccharide-induced hepatocyte injury: dissociation between in vivo and in vitro effects [J]. Int J Immunopharmacol, 2003, 3 (12) : 1627-1638.
[19] Palmes D, Spiegel HU. Animalmodels of liver regeneration [J]. Biomaterials, 2004, 25 (9) : 1601-1611.
[20] Katsumi M, Kenta K, Kazunori M, et al, Alanine protects liver from injury caused by D-galactosamine and CCl4 [J]. Hepatology, 1996, 24 (1) : 185-191.
[21] Edde L, Zhou XJ , Eaton JW. Induction of nitric oxide synthase in macrophages: inhibition by fructose-1,6-diphosphate [J]. Biochem Biophys Res Commun, 1998, 243 (3) : 683-687.